Health Care • Biotechnology: Pharmaceutical Preparations
$0.85 ▼ -0.09
(-9.66%)
MKT CAP: $27.6M • VOL: 496.8K
52W L $1 52W H $3
ROARABLE / RQD
E • 34/100
PIOTROSKI
1 / 9
CELU // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $26.6M | $54.2M | $22.8M |
| YoY Revenue Growth % | -51.0% | +138.1% | — |
| Gross Profit | $6.5M | $39.2M | — |
| Gross Margin % | 24.4% | 72.4% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$61.3M | -$38.4M | -$192.3M |
| Operating Margin % | -80.0% | -70.7% | -80.0% |
| Net Income (GAAP) | -$91.7M | -$57.9M | -$196.3M |
| EBITDA (Normalized) | — | -$38.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$13.3M | -$6.4M | -$38.7M |
| Capital Expenditures (CapEx) | — | $161.0K | — |
| Free Cash Flow (FCF) | -$13.3M | -$6.6M | -$38.7M |
| FCF Margin % | -49.9% | -12.1% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $6.2M | $738.0K | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$38.1M | $8.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CELU.